Cipla Limited (CIPLA) — Announcement | 18 July 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
USFDA inspection of InvaGen subsidiary completed with one Form 483 observation
💡 Investor Takeaway
The inspection outcome poses minimal immediate risk as the company plans to resolve the observation promptly.
⚠️ Risks
Potential regulatory scrutiny of manufacturing operations

Cipla announced a USFDA inspection of its InvaGen subsidiary in New York from July 13-17, 2026, which identified one Form 483 observation but confirmed the company will address it within the required timeframe.

📄 View Original Announcement (PDF)

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day